The definitive directory of AI-native and computational drug discovery companies, spanning generative chemistry, computational biology, target identification, protein design, clinical AI, drug repurposing, and phenomics and high-content screening. Curated for biotech investors, pharma partners scouting AI platforms, and scientists tracking machine learning in drug development.
BioMed Nexus tracks 161 AI drug discovery companies across 7 categories: generative chemistry, computational biology, target identification, protein design, clinical AI, drug repurposing, and phenomics & screening. The directory covers the leading AI-native drug discovery companies, including Recursion, Insilico Medicine, Schrödinger, Relay Therapeutics, Atomwise and Absci, alongside emerging startups. Last updated July 2026
Every listing here is free by name. Add a Verified Listing ($495 per year) with a tagline, website link, and verified badge, or go Featured for your logo, full description, and priority placement at the top of this directory. Data Partners also get a dedicated landing page and a sponsored spotlight in a daily brief reaching about 43,000 recipients.
Featured spots are limited per category.
Right now, every company in this directory is just a name in a database. Featured partners get a full profile with logo, platform, pipeline, backlinks, and priority placement at the very top of this page. Claim the top spot before your competitors do. A Verified Listing is the lighter option: your tagline, website link, and verified badge for $495 per year.
The BioMed Nexus AI Drug Discovery Companies Directory is a comprehensive, regularly updated list of AI-native and computational drug discovery companies, spanning generative chemistry, computational biology, target identification, protein design and engineering, clinical AI, drug repurposing, and phenomics and high-content screening. It covers the leading AI drug discovery companies alongside emerging startups applying machine learning to therapeutics.
Use it to research AI drug discovery companies by approach, track the competitive landscape, and map platform and partnership opportunities. Whether you are a biotech investor evaluating the AI drug discovery sector, a pharma partner scouting AI platforms, or a scientist tracking machine learning in drug development, the directory provides structured, current company data. Curated and maintained by the BioMed Nexus editorial team; last updated July 2026.
Companies can claim a free listing by name or add a Verified Listing ($495 per year) with a tagline, website link, and verified badge. Featured Profiles and Data Partners get priority placement, and Data Partners add a dedicated landing page and a sponsored spotlight in the BioMed Nexus daily brief, which reaches about 43,000 recipients per weekday edition. Contact our partnerships team to learn more.
